A number of first-in-disease, first-in-class and first-in-modality drugs approved last year have redefined therapeutic areas, ...

Xanomeline and trospium chloride (KarXT), a novel M1/M4 muscarinic receptor agonist, significantly improves cognitive ...

Zai Lab Limited today announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults. "There ...

Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc.

Patient enrollment is completed ahead of schedule for Contineum's Phase 2 clinical trial of PIPE-307, an oral remyelination ...

Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) yesterday and set a ...

Cambridge Cognition announced the use of its ‘CANTAB’ cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for ‘Cobenfy’, a newly FDA-approved treatment ...

Drugs for metabolic diseases, vaccines, and cancer therapies feature among new product launches this year that could top $1 ...

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group, congratulates Bristol Myers Squibb, the global biopharmaceutical company, for its recent FDA approval of Cobenfy (KarXT™ ...